2025年医保目录调整“上新” 满足群众多层次、多元化用药需求

Core Points - The National Healthcare Security Administration (NHSA) announced that the new basic medical insurance drug list and the first commercial insurance innovative drug list will be released online and offline in Guangzhou on the first weekend of December, with implementation starting January 1, 2024 [1] - The recent negotiations involved 120 domestic and foreign enterprises, with 127 drugs outside the basic medical insurance drug list and 24 drugs for the commercial insurance innovative drug list participating in price negotiations [3] - The commercial insurance innovative drug list was established to better meet the diverse medication needs of the public, with 121 high-value drugs approved through this new list [7] Industry Insights - The commercial health insurance market in China is experiencing rapid growth, with the original insurance premium income reaching 977.3 billion yuan in 2024, an increase of 8.2% year-on-year [7] - The total expenditure of the basic medical insurance fund is projected to reach 2.97 trillion yuan in 2024, providing solid support for healthcare services [7] - The NHSA is exploring solutions to synchronize settlements between basic medical insurance and commercial health insurance, with several regions already implementing one-stop payment platforms [9]